This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D59.5 | Synonyms: PNH, Marchiafava-Micheli syndrome, Paroxysmal nocturnal hemoglobinuria, GPI-deficient blood cell disorder
Paroxysmal nocturnal hemoglobinuria (PNH) was first described in 1882 by William Gull in a patient with hematuria and anemia, and in 1928 the Italian physicians Ettore Marchiafava and Alessio Micheli systematically described the clinical features of this syndrome. It is also called 'Marchiafava-Micheli syndrome' after them. Initially, paroxysmal nocturnal hemoglobinuria was recognized as the characteristic symptom, but it was later found that nocturnal hemoglobinuria actually appears in only about 25% of all patients.
In 1937, Ham and Dingle discovered that PNH red blood cells are selectively lysed in acidified serum and developed the 'Ham test (acid hemolysis test)'. Subsequently, in the 1960s–1970s, Rosse et al. established that PNH red blood cells are abnormally susceptible to complement activation and proposed that this is related to a deficiency of GPI (glycosylphosphatidylinositol)-anchored proteins.
In 1993, Miyata et al. and Takeda et al. identified PIGA, the causative gene of PNH. The PIGA gene encodes the enzyme that catalyzes the first step of GPI anchor biosynthesis and is located on the X chromosome. It was revealed that somatic PIGA variants cause a deficiency of GPI-anchored proteins (CD55, CD59, etc.), resulting in complement susceptibility.
In 2007, eculizumab (a terminal complement C5 inhibitor) was first approved by the FDA as a treatment for PNH, shifting the paradigm of PNH treatment. The introduction of eculizumab achieved suppression of hemolysis, prevention of thrombosis, and improved survival.
The cause of PNH is an acquired (somatic) variant of the PIGA gene in hematopoietic stem cells. Because the PIGA gene is located on the X chromosome, in males (XY) a variant in a single PIGA allele alone completely blocks GPI synthesis. In females (XX), a single PIGA variant can also be clinically expressed due to X inactivation (lyonization).
When GPI anchor biosynthesis is halted by PIGA variants, all of the more than 50 cell surface proteins that depend on the GPI anchor become deficient. The most important in PNH pathology is the deficiency of the complement regulatory proteins CD55 (DAF, decay-accelerating factor) and CD59 (MAC-inhibitory protein). CD55 inhibits the formation of C3/C5 convertases, and CD59 inhibits the formation of the MAC (membrane attack complex).
The reason PNH hematopoietic stem cell clones have a proliferative advantage over normal hematopoietic stem cells is explained by immune escape. It is understood that, under the autoimmune T-cell attack associated with aplastic anemia, GPI-deficient clones have a relative survival advantage and expand selectively.
PNH is a clonal hematologic disease caused by acquired somatic variants. Because it is not a germline variant, it is not inherited. PIGA variants arise in hematopoietic stem cells, and GPI deficiency appears in all blood cells (red blood cells, white blood cells, platelets) derived from that clone.
| PNH clone size | Clinical significance | Thrombosis risk |
|---|---|---|
| 1~10% | Small clone, asymptomatic or mild symptoms | Low |
| 10~50% | Moderate symptoms (hemolysis, anemia) | Moderate |
| 50% or more | Severe PNH, hemoglobinuria | Markedly increased |
PNH and aplastic anemia (AA) are closely associated. Small PNH clones are found in 30–50% of AA patients, and conversely, some PNH patients progress to aplastic anemia. These two diseases are understood as conditions on a continuum that share autoimmune-mediated suppression of hematopoiesis and immune escape of the PNH clone.
PNH is a rare disease with an estimated incidence of 1–2 per million population per year. It is estimated that there are about 10,000–20,000 patients worldwide. The incidence in Western countries is about 1 per million, but relatively higher incidence is reported in East Asia (Korea, Japan, China, Thailand) due to the association with aplastic anemia.
In Korea, PNH is managed as a rare hematologic disease. According to domestic studies, the frequency of PNH clones is high in patients with aplastic anemia, a phenomenon commonly observed in East Asian populations. Registration and management of patients treated with eculizumab are carried out mainly at specialized hematology centers in Korea, and it is eligible for the rare disease Special Copayment Reduction.
PNH occurs mainly in young adults (median age of onset 35–40 years), but also occurs in children and the elderly. There is no clear sex difference, but pregnancy-related exacerbation of PNH occurs characteristically in women.
Because of CD59 and CD55 deficiency, PNH red blood cells are susceptible to the MAC formed by continuous low-level activation (tick-over) of the alternative complement pathway. In particular, the origin of the name 'paroxysmal nocturnal' is that mild acidosis caused by reduced respiration during sleep promotes complement activation, increasing intravascular hemolysis at night. In reality, continuous intravascular hemolysis is ongoing and is not limited to nighttime.
In PNH, thrombosis is one of the main causes of death. The mechanism of thrombosis is multifactorial. ① Due to GPI deficiency in platelets, CD59 is absent, so platelets are activated by complement, increasing aggregation. ② Free hemoglobin from intravascular hemolysis consumes NO (nitric oxide), reducing vasodilation and increasing platelet activation. ③ Increased tissue factor expression activates coagulation. Thrombi occur in both veins (hepatic veins, portal vein, cerebral venous sinuses, mesenteric veins) and arteries.
Free hemoglobin released by intravascular hemolysis rapidly consumes plasma NO, and released arginase degrades L-arginine, the NO precursor. NO depletion causes symptoms such as smooth muscle spasm, esophageal spasm, abdominal pain, erectile dysfunction, renal vasoconstriction, and hypertension.
Fatigue, pallor, and dyspnea appear as symptoms of chronic anemia. Hemoglobinuria: the typical symptom is red to brown urine as hemoglobin is excreted in the urine due to intravascular hemolysis (in reality, only about 25% of patients experience it). Jaundice (elevated indirect bilirubin). Abdominal pain, back pain, dysphagia (esophageal spasm), and erectile dysfunction occur due to smooth muscle spasm from NO depletion.
Thrombosis is the most serious complication and a main cause of death in PNH. Hepatic vein thrombosis (Budd-Chiari syndrome, about 40%), portal vein thrombosis, cerebral venous sinus thrombosis, and mesenteric vein thrombosis are characteristic. Arterial thrombosis (stroke, myocardial infarction) also occurs. Thrombotic events can also present acutely and are life-threatening.
When PNH is accompanied by aplastic anemia, pancytopenia appears. Recurrent infections due to leukopenia and bleeding due to thrombocytopenia are the main symptoms.
Pallor, jaundice, and hemoglobinuria (change in urine color) are the main physical signs. Splenomegaly is rare. When Budd-Chiari syndrome develops, abdominal distension, ascites, hepatomegaly, and abdominal tenderness are observed. When cerebral venous sinus thrombosis develops, headache, signs of increased intracranial pressure, and altered consciousness appear.
Complete blood count: depending on severity, normal to severe anemia (Hb 5–11 g/dL), thrombocytopenia, leukopenia (with accompanying AA). Blood smear: normocytic normochromic anemia, increased reticulocytes (hemolytic response). Biochemistry: markedly elevated LDH (a sensitive marker of intravascular hemolysis), decreased or absent haptoglobin, elevated indirect bilirubin, decreased serum iron. Urinalysis: hemoglobinuria, hemosiderinuria.
Classification of GPI-deficient blood cells on peripheral blood flow cytometry: PNH type III (complete GPI deficiency), type II (partial GPI deficiency), type I (normal). The FLAER (fluorescent aerolysin) assay is the standard method for quantifying PNH clones in white blood cells. The proportion of CD59-deficient red blood cells correlates with clinical severity.
PNH screening is performed in the following clinical situations: ① unexplained hemolytic anemia, ② unexplained thrombocytopenia, ③ unexplained thrombosis (especially at unusual sites), ④ aplastic anemia, ⑤ refractory anemia (MDS), ⑥ anemia accompanied by abdominal pain/erectile dysfunction/dysphagia, ⑦ patients with hemoglobinuria.
Peripheral blood flow cytometry is the standard method for PNH screening. GPI-deficient cells are quantified using CD55, CD59 (red blood cells), FLAER, CD14, CD16 (white blood cell lineages). High-sensitivity analysis capable of detecting a clone size of 0.01% or more is recommended.
The Ham test was formerly the standard for PNH diagnosis, but it has now been replaced by flow cytometry, which is more sensitive and accurate. However, it is still used in some resource-limited settings.
High-sensitivity flow cytometry is the standard for PNH diagnosis and quantification of clone size. GPI-deficient cells in white blood cells (neutrophils, monocytes) are quantified using FLAER/LAIP (fluorescent aerolysin, lineage-associated immunophenotyping). CD59-deficient red blood cells are also quantified. A PNH clone size of 1% or more (intermediate or greater) is considered clinically significant.
When accompanying aplastic anemia is suspected, bone marrow aspiration and biopsy are performed. Bone marrow cellularity, cell morphology, and chromosomal analysis are essential to determine whether AA and MDS are present.
Hemolytic anemia: autoimmune hemolytic anemia (positive direct Coombs test), hereditary spherocytosis, G6PD deficiency, etc. Thrombotic microangiopathy (TMA): TTP (decreased ADAMTS13), aHUS (complement variants). Aplastic anemia: bone marrow failure with accompanying PNH clone. Myelodysplastic syndrome (MDS): abnormal blood cell morphology, chromosomal abnormalities.
Eculizumab is a C5-inhibiting monoclonal antibody approved by the FDA as a treatment for PNH in 2007. Eculizumab markedly reduces intravascular hemolysis, lowers thrombosis risk, reduces transfusion dependence, and improves quality of life. Administration: an initial induction dose (600 mg, weekly for 4 weeks) followed by a maintenance dose (900 mg, every 2 weeks). Meningococcal vaccination is mandatory before starting treatment.
A long-acting C5 inhibitor whose half-life is 4 times longer than that of eculizumab, allowing administration every 8 weeks. It shows efficacy equivalent to eculizumab while reducing dosing frequency, increasing patient convenience. FDA approved in 2019.
Proximal complement inhibitors such as pegcetacoplan (a C3 inhibitor, FDA approved in 2021) and danicopan (an oral factor D inhibitor) have been developed as new treatment options that additionally suppress the extravascular hemolysis that persists during eculizumab treatment.
Transfusion (packed red blood cells): supportive care for severe anemia. Folic acid supplementation: replaces folate depleted by chronic hemolysis. Anticoagulation therapy: long-term anticoagulation when thrombosis occurs or in high-risk patients. Allogeneic hematopoietic stem cell transplantation is the only cure for PNH, but since the advent of eculizumab it is performed only in selected patients (severe PNH + aplastic anemia, HLA-matched sibling donor).
Before eculizumab, the median survival of PNH was poor, at about 10–15 years after diagnosis. The main causes of death were thrombosis (35–40%), bone marrow failure (infection, bleeding, about 30%), and transformation (MDS or acute leukemia, 5–10%). The 5-year survival rate was only about 60–70%.
The survival rate of PNH patients treated with eculizumab has improved to a level almost equivalent to that of the general population. Intravascular hemolysis is suppressed by 95% or more, thrombotic events are markedly reduced, and transfusion dependence is greatly reduced. However, because eculizumab does not eliminate the PNH clone itself, long-term treatment is required.
In some PNH patients (about 15–20%), spontaneous remission, in which the PNH clone spontaneously disappears or decreases, has been reported. Transformation to MDS or acute myeloid leukemia occurs in less than 1%.
In PNH, prevention of thrombosis is key to improving prognosis. In patients with a clone size of 50% or more or at high risk, combining anticoagulation therapy (warfarin, low-molecular-weight heparin) with eculizumab treatment is recommended. Because eculizumab treatment itself markedly lowers thrombosis risk, the need for anticoagulation in patients receiving eculizumab is determined individually.
In patients treated with eculizumab/ravulizumab, the risk of infection with encapsulated bacteria, including meningococcus, is greatly increased. Vaccination with the quadrivalent meningococcal vaccine (MenACWY) and the meningococcal B vaccine before starting treatment is mandatory. Revaccination every 3–5 years during treatment is recommended.
In PNH patients, pregnancy markedly increases thrombosis risk. Adequate counseling and an eculizumab treatment plan are needed before planning pregnancy. Data on the safety of eculizumab use during pregnancy are accumulating, and many centers currently recommend continuing eculizumab treatment during pregnancy.
In PNH patients, regular flow cytometry (monitoring of clone size), LDH, blood counts, and monitoring for thrombotic symptoms are needed. Treatment intensity is adjusted according to changes in clone size and clinical symptoms.